Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.
OBJECTIVE
Evaluate the efficacy of intravitreal pegaptanib sodium (Macugen) in refractory pseudophakic cystoid macular oedema (CME).


METHODS
Prospective, nonrandomized, interventional case series. Four eyes of four patients with refractory pseudophakic CME to pars plana vitrectomy and intravitreal bevacizumab and triamcinolone, were treated with pegaptanib sodium, with a mean follow up of 4 months. Pre- and postinfection examinations included assessment of best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study chart (ETDRS), fluorescein angiography (FA), and optical coherence tomography (OCT).


RESULTS
Visual acuity increased in all patients after intravitreal pegaptanib sodium. OCT showed improvement of the retinal thickness in the macular area.


CONCLUSIONS
Intravitreal pegaptanib sodium (Macugen) is a promising treatment for pseudophakic cystoid macular oedema resistant to other medical treatment strategies. However, further study is needed to assess the treatment's long term efficacy and the need for retreatment.
Cervera
E
E
Department of Ophthalmology, Hospital General de Valencia, Valencia, Spain.
Diaz-Llopis
M
M
Udaondo
P
P
Garcia-Delpech
S
S
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000150:complications; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019591:Pseudophakia / Q000150:complications*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014821:Vitrectomy / Q000009:adverse effects
D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; C495058:pegaptanib